Peptides Corresponding to the Predicted Heptad Repeat 2 Domain of the Feline Coronavirus Spike Protein Are Potent Inhibitors of Viral Infection

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Dec 7

PMID 24312629

Citations 16

Authors

I-Jung Liu

Wan-Ting Tsai

Li-En Hsieh

Ling-Ling Chueh

Affiliations

Soon will be listed here.

Abstract

Background: Feline infectious peritonitis (FIP) is a lethal immune-mediated disease caused by feline coronavirus (FCoV). Currently, no therapy with proven efficacy is available. In searching for agents that may prove clinically effective against FCoV infection, five analogous overlapping peptides were designed and synthesized based on the putative heptad repeat 2 (HR2) sequence of the spike protein of FCoV, and the antiviral efficacy was evaluated.

Methods: Plaque reduction assay and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cytotoxicity assay were performed in this study. Peptides were selected using a plaque reduction assay to inhibit Feline coronavirus infection.

Results: The results demonstrated that peptide (FP5) at concentrations below 20 μM inhibited viral replication by up to 97%. The peptide (FP5) exhibiting the most effective antiviral effect was further combined with a known anti-viral agent, human interferon-α (IFN-α), and a significant synergistic antiviral effect was observed.

Conclusion: Our data suggest that the synthetic peptide FP5 could serve as a valuable addition to the current FIP prevention methods.

Citing Articles

Feline Infectious Peritonitis: European Advisory Board on Cat Diseases Guidelines.

Tasker S, Addie D, Egberink H, Hofmann-Lehmann R, Hosie M, Truyen U Viruses. 2023; 15(9).

PMID: 37766254 PMC: 10535984. DOI: 10.3390/v15091847.

Surface Display of Peptides Corresponding to the Heptad Repeat 2 Domain of the Feline Enteric Coronavirus Spike Protein on Spores Elicits Protective Immune Responses Against Homologous Infection in a Feline Aminopeptidase-N-Transduced Mouse Model.

Chen C, Li Y, Lv F, Xu L, Huang Y Front Immunol. 2022; 13:925922.

PMID: 35837396 PMC: 9273865. DOI: 10.3389/fimmu.2022.925922.

Known Cellular and Receptor Interactions of Animal and Human Coronaviruses: A Review.

Everest H, Stevenson-Leggett P, Bailey D, Bickerton E, Keep S Viruses. 2022; 14(2).

PMID: 35215937 PMC: 8878323. DOI: 10.3390/v14020351.

Feline Coronavirus Antivirals: A Review.

Delaplace M, Huet H, Gambino A, Le Poder S Pathogens. 2021; 10(9).

PMID: 34578182 PMC: 8469112. DOI: 10.3390/pathogens10091150.

Animal Coronavirus Diseases: Parallels with COVID-19 in Humans.

Lin C, Chan K, Ooi E, Chiou M, Hoang M, Hsueh P Viruses. 2021; 13(8).

PMID: 34452372 PMC: 8402828. DOI: 10.3390/v13081507.

References

Xu Y, Liu Y, Lou Z, Qin L, Li X, Bai Z . Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core. J Biol Chem. 2004; 279(29):30514-22. PMC: 7982547. DOI: 10.1074/jbc.M403760200. View

McDonagh P, Sheehy P, Norris J . In vitro inhibition of feline coronavirus replication by small interfering RNAs. Vet Microbiol. 2011; 150(3-4):220-9. PMC: 7117188. DOI: 10.1016/j.vetmic.2011.01.023. View

Regan A, Shraybman R, Cohen R, Whittaker G . Differential role for low pH and cathepsin-mediated cleavage of the viral spike protein during entry of serotype II feline coronaviruses. Vet Microbiol. 2008; 132(3-4):235-48. PMC: 2588466. DOI: 10.1016/j.vetmic.2008.05.019. View

Liu I, Kao C, Hsieh S, Wey M, Kan L, Wang W . Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. Antiviral Res. 2008; 81(1):82-7. PMC: 7114320. DOI: 10.1016/j.antiviral.2008.10.001. View

Jiang S, Lin K, Strick N, Neurath A . HIV-1 inhibition by a peptide. Nature. 1993; 365(6442):113. DOI: 10.1038/365113a0. View

Hartmann K, Ritz S . Treatment of cats with feline infectious peritonitis. Vet Immunol Immunopathol. 2008; 123(1-2):172-5. PMC: 7132371. DOI: 10.1016/j.vetimm.2008.01.026. View

van der Meer F, de Haan C, Schuurman N, Haijema B, Verheije M, Bosch B . The carbohydrate-binding plant lectins and the non-peptidic antibiotic pradimicin A target the glycans of the coronavirus envelope glycoproteins. J Antimicrob Chemother. 2007; 60(4):741-9. PMC: 7110056. DOI: 10.1093/jac/dkm301. View

Medinas R, Lambert D, Tompkins W . C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. J Virol. 2002; 76(18):9079-86. PMC: 136458. DOI: 10.1128/jvi.76.18.9079-9086.2002. View

Pan C, Lu H, Qi Z, Jiang S . Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors. AIDS. 2009; 23(5):639-41. PMC: 2695507. DOI: 10.1097/QAD.0b013e328325a4cd. View

10.

Yuan K, Yi L, Chen J, Qu X, Qing T, Rao X . Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. Biochem Biophys Res Commun. 2004; 319(3):746-52. PMC: 7111000. DOI: 10.1016/j.bbrc.2004.05.046. View

11.

Bosch B, Martina B, van der Zee R, Lepault J, Haijema B, Versluis C . Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc Natl Acad Sci U S A. 2004; 101(22):8455-60. PMC: 420415. DOI: 10.1073/pnas.0400576101. View

12.

Pang W, Tam S, Zheng Y . Current peptide HIV type-1 fusion inhibitors. Antivir Chem Chemother. 2009; 20(1):1-18. DOI: 10.3851/IMP1369. View

13.

Root M, Kay M, Kim P . Protein design of an HIV-1 entry inhibitor. Science. 2001; 291(5505):884-8. DOI: 10.1126/science.1057453. View

14.

Kielian M, Rey F . Virus membrane-fusion proteins: more than one way to make a hairpin. Nat Rev Microbiol. 2005; 4(1):67-76. PMC: 7097298. DOI: 10.1038/nrmicro1326. View

15.

Carstens E . Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2009). Arch Virol. 2009; 155(1):133-46. PMC: 7086975. DOI: 10.1007/s00705-009-0547-x. View

16.

He Y, Xiao Y, Song H, Liang Q, Ju D, Chen X . Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem. 2008; 283(17):11126-34. DOI: 10.1074/jbc.M800200200. View

17.

Miller E, Harrison J, Radoshitzky S, Higgins C, Chi X, Dong L . Inhibition of Ebola virus entry by a C-peptide targeted to endosomes. J Biol Chem. 2011; 286(18):15854-61. PMC: 3091195. DOI: 10.1074/jbc.M110.207084. View

18.

Haagmans B, Osterhaus A . Coronaviruses and their therapy. Antiviral Res. 2006; 71(2-3):397-403. PMC: 7114240. DOI: 10.1016/j.antiviral.2006.05.019. View

19.

Weiss R, Cox N, Boudreaux M . Toxicologic effects of ribavirin in cats. J Vet Pharmacol Ther. 1993; 16(3):301-16. PMC: 7167023. DOI: 10.1111/j.1365-2885.1993.tb00177.x. View

20.

Weiss R, Toivio-Kinnucan M . Inhibition of feline infectious peritonitis virus replication by recombinant human leukocyte (alpha) interferon and feline fibroblastic (beta) interferon. Am J Vet Res. 1988; 49(8):1329-35. View